{
    "paper_id": "PMC7195032",
    "metadata": {
        "title": "Covid-19: The challenges facing endocrinology",
        "authors": [
            {
                "first": "Michel",
                "middle": [],
                "last": "Pugeat",
                "suffix": "",
                "email": "michel.pugeat@chu-lyon.fr",
                "affiliation": {}
            },
            {
                "first": "Olivier",
                "middle": [],
                "last": "Chabre",
                "suffix": "",
                "email": "OlivierChabre@chu-grenoble.fr",
                "affiliation": {}
            },
            {
                "first": "Marie-Christine",
                "middle": [],
                "last": "Van Tyghem",
                "suffix": "",
                "email": "mc-vantyghem@chru-lille.fr",
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "The Covid-19 pandemic has hit the planet like a tidal wave, imperiling the lives of thousands and threatening health systems with collapse. In this issue of the Annals of Endocrinology, Alexandre et al. [1] remind us that the gateway to Sars-CoV-2 is the angiotensin II converting enzyme (ACE2), physiological regulator of the renin-angiotensin system (RAS). Angiotensin II stimulates the secretion of aldosterone via the AT1 receptor of the adrenal gland (glomerulated zone) and has its own vasoconstrictive, pro-fibrosing, pro-inflammatory activity. ACE2 converts angiotensin II-[1\u20138] to angiotensin-[1\u20137], which has properties opposite to those of angiotensin II, and is therefore a negative regulator of the RAS. The legitimate question raised by the authors is whether the prescription of converting enzyme inhibitor [1\u201310] (ACEi) and angiotensin receptor type 1 blockers (ARAII), very widely used in hypertension treatment, may increase the risk of developing severe acute respiratory syndrome in Covid-19-infected patients. It is convincingly explained why, on the basis of the available evidence, scientific societies do not recommend discontinuation of hypertension treatment by ACEi and ARAIIs in Covid-19+ patients. Therapeutic prospects and the first trials of the use of the soluble form of ACE2 as a virus trap are underway.",
            "cite_spans": [
                {
                    "start": 203,
                    "end": 206,
                    "mention": "[1]",
                    "ref_id": "BIBREF0"
                }
            ],
            "section": "English version",
            "ref_spans": []
        },
        {
            "text": "Covid-19 challenges the endocrinologist in many ways. Three in particular are worth raising here:\u2022the relative protection of children, presumed to be healthy carriers, and the lower incidence of death in women (1/3) suggest that the hormonal environment and genetic aspects are factors for surviving Covid-19. We know for example that the TLR7 gene present on the X chromosome is a receptor which influences antiviral response [2]. Paradoxically, as immune response is stronger in women, contributing to greater susceptibility to autoimmune disease, this flaw becomes an advantage over viral infection. In men, who make up more than two-thirds of deaths from Covid-19, risk is higher after 50 years and even more after 70 years. But age is not the only factor; a context of metabolic syndrome with overweight, diabetes and hypertension seems to be strongly associated with this risk. It is important to remember that the decline in testosterone secretion in humans can be explained by 4 factors: age, obesity, associated comorbidities, and smoking [3]. Strangely, the ACE2 protein is expressed in many tissues, including the testicle [4]. These avenues could be explored to better identify the influence of sex hormones on the ability to resist viral disease;\u2022a cytokine storm is reported during the respiratory distress phase in 20% of Covid-19 + patients with multi-organ failure and hypotension refractory to standard treatment [5]. How does the adrenal cortex function react in this critical situation? Is there an analogy with what has been well described in septic shock? [6]. We already know that corticosteroids are not useful in the treatment of pulmonary lesions associated with severe respiratory distress, and are indeed deleterious by delaying elimination of the virus. Is there any form of resistance to glucocorticoids?\u2022the Covid-19 epidemic has served as an opportunity to adopt teleconsultation to respond to the urgent need for continuity of care. This is bound to lead to reimagining a definitive shift to telemedicine in the management of chronic diseases, which is liable to disrupt our practice and teaching and also the entire economic system of health-care.\n",
            "cite_spans": [
                {
                    "start": 427,
                    "end": 430,
                    "mention": "[2]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 1048,
                    "end": 1051,
                    "mention": "[3]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 1134,
                    "end": 1137,
                    "mention": "[4]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 1431,
                    "end": 1434,
                    "mention": "[5]",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 1578,
                    "end": 1581,
                    "mention": "[6]",
                    "ref_id": "BIBREF5"
                }
            ],
            "section": "English version",
            "ref_spans": []
        },
        {
            "text": "Endocrinologists and diabetologists, like many other specialists, must prepare for this very immediate deadline.",
            "cite_spans": [],
            "section": "English version",
            "ref_spans": []
        },
        {
            "text": "In this issue of the Annals of Endocrinology, the reader will find the answers to the questions posed by aging, which is the center of attention of the whole medical community, in the management of thyroid diseases. This consensus statement, coordinated by Philippe Caron, is remarkable, practical and exhaustive. It is based on the extensive clinical experience of its authors.",
            "cite_spans": [],
            "section": "English version",
            "ref_spans": []
        },
        {
            "text": "La pand\u00e9mie de Covi19 s\u2019est abattue sur la plan\u00e8te comme une d\u00e9ferlante qui menace la vie de milliers d\u2019individus avec le risque d\u2019explosion des syst\u00e8mes de sant\u00e9. Dans ce num\u00e9ro des Annales d\u2019Endocrinologie, Alexandre et al. [1] nous rappelle que la porte d\u2019entr\u00e9e du Sars-CoV-2 est l\u2019enzyme de conversion de l\u2019angiotensine II (ACE2) r\u00e9gulateur physiologique du syst\u00e8me r\u00e9nine-angiotensine (SRA). L\u2019angiotensine II stimule la s\u00e9cr\u00e9tion d\u2019aldost\u00e9rone via le r\u00e9cepteur AT1 de la surr\u00e9nale (zone glom\u00e9rul\u00e9e) et poss\u00e8de une activit\u00e9 propre vasoconstrictrice, pro-fibrosante, et pro-inflammatoire. L\u2019ACE2 en convertissant l\u2019angiotensine II [1\u20138] en angiotensine [1\u20137], qui a des propri\u00e9t\u00e9s oppos\u00e9es \u00e0 celles de l\u2019angiotensine II, est donc un r\u00e9gulateur n\u00e9gatif du syst\u00e8me r\u00e9nine-angiotensine. La question l\u00e9gitime soulev\u00e9e par les auteurs est de savoir si la prescription d\u2019inhibiteur de l\u2019enzyme de conversion [1\u201310] (IEC) et les bloqueurs du r\u00e9cepteur de type 1 \u00e0 l\u2019angiotensine (ARAII), tr\u00e8s largement utilis\u00e9s dans le traitement de l\u2019hypertension, pourraient augmenter le risque de d\u00e9velopper un syndrome respiratoire aigu s\u00e9v\u00e8re en cas d\u2019infection au COVID-19. Il est expliqu\u00e9 de fa\u00e7on convaincante pourquoi, sur la base des preuves disponibles, les soci\u00e9t\u00e9s savantes ne recommandent pas l\u2019interruption des traitements de l\u2019hypertension art\u00e9rielle par IEC et ARAII chez les patients Covi19+. Les perspectives th\u00e9rapeutiques et les premiers essais de l\u2019utilisation de la forme soluble d\u2019ACE2 comme pi\u00e8ge de virus sont en cours.",
            "cite_spans": [
                {
                    "start": 226,
                    "end": 229,
                    "mention": "[1]",
                    "ref_id": "BIBREF0"
                }
            ],
            "section": "Version fran\u00e7aise",
            "ref_spans": []
        },
        {
            "text": "Le Covi-19 interpelle l\u2019endocrinologue par bien des aspects. Trois peuvent \u00eatre identifi\u00e9s:\u2022la relative protection des enfants, pr\u00e9sum\u00e9s porteurs sains, et la moindre incidence de d\u00e9c\u00e8s chez la femme (1/3) sugg\u00e8rent que l\u2019environnement hormonal et des facteurs g\u00e9n\u00e9tiques pourraient compter parmi les facteurs de chance de survivre au Covid-19. On sait par exemple que le g\u00e8ne TLR7 pr\u00e9sent sur le chromosome X est un r\u00e9cepteur qui influence la r\u00e9ponse antivirale [2]. Paradoxalement, si la r\u00e9ponse immunitaire est plus forte chez la femme ce qui contribue \u00e0 une plus grande susceptibilit\u00e9 au d\u00e9veloppement de maladies auto-immunes, cette aptitude devient un avantage vis \u00e0 vis de l\u2019infection virale. Chez l\u2019homme qui repr\u00e9sente plus de 2/3 des d\u00e9c\u00e8s lors du Covid-19, le risque est plus \u00e9lev\u00e9 \u00e0 50 ans et plus encore apr\u00e8s 70 ans. Mais l\u2019\u00e2ge n\u2019est pas le seul facteur, le contexte de syndrome m\u00e9tabolique avec surpoids, diab\u00e8te et hypertension semble en grande partie associ\u00e9 \u00e0 ce risque. Il est important de noter que le d\u00e9clin de la s\u00e9cr\u00e9tion de testost\u00e9rone chez l\u2019homme s\u2019explique par 4 facteurs: l\u2019\u00e2ge, l\u2019ob\u00e9sit\u00e9, les comorbidit\u00e9s associ\u00e9es et le tabac [3]. Curieusement la prot\u00e9ine ACE2 est exprim\u00e9e dans de nombreux tissus dont le testicule [4]. Ces pistes pourraient \u00eatre explor\u00e9es pour mieux identifier l\u2019influence des hormones sexuelles sur la capacit\u00e9 de se d\u00e9fendre contre les maladies virales;\u2022un orage de cytokines a \u00e9t\u00e9 d\u00e9crit lors de la phase de d\u00e9tresse respiratoire dans 20 % des patients Covid-19 + avec une d\u00e9faillance multi-organique et hypotension r\u00e9fractaire au traitement standard [5]. Comment la fonction corticosurr\u00e9nale r\u00e9agit-elle dans cette situation critique? Y-a-t-il une analogie avec ce qui a \u00e9t\u00e9 bien d\u00e9crit au cours du choc septique? [6]. On sait d\u00e9j\u00e0 que les cortico\u00efdes ne sont pas utiles voir d\u00e9l\u00e9t\u00e8res, en retardant l\u2019\u00e9limination du virus, dans le traitement des l\u00e9sions pulmonaires associ\u00e9es au tableau de d\u00e9tresse respiratoire s\u00e9v\u00e8res [7]. Existe-t-il une forme de r\u00e9sistance aux glucocortico\u00efdes?\u2022l\u2019\u00e9pid\u00e9mie de Covid-19 a cr\u00e9\u00e9 l\u2019opportunit\u00e9 d\u2019adopter les consultations t\u00e9l\u00e9phoniques pour r\u00e9pondre \u00e0 l\u2019urgence de la continuit\u00e9 des soins [8]. Il s\u2019en suivra une r\u00e9flexion sur la p\u00e9rennit\u00e9 de l\u2019usage de la t\u00e9l\u00e9m\u00e9decine dans la prise en charge des maladies chroniques qui bouleverserait \u00e0 la fois nos pratiques et son enseignement mais aussi tout le syst\u00e8me \u00e9conomique de sant\u00e9. Les endocrinologues et les diab\u00e9tologues comme beaucoup de sp\u00e9cialistes doivent se pr\u00e9parer \u00e0 cette \u00e9ch\u00e9ance imm\u00e9diate.\n",
            "cite_spans": [
                {
                    "start": 463,
                    "end": 466,
                    "mention": "[2]",
                    "ref_id": "BIBREF1"
                },
                {
                    "start": 1158,
                    "end": 1161,
                    "mention": "[3]",
                    "ref_id": "BIBREF2"
                },
                {
                    "start": 1248,
                    "end": 1251,
                    "mention": "[4]",
                    "ref_id": "BIBREF3"
                },
                {
                    "start": 1605,
                    "end": 1608,
                    "mention": "[5]",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 1769,
                    "end": 1772,
                    "mention": "[6]",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 1976,
                    "end": 1979,
                    "mention": "[7]",
                    "ref_id": "BIBREF6"
                },
                {
                    "start": 2178,
                    "end": 2181,
                    "mention": "[8]",
                    "ref_id": "BIBREF7"
                }
            ],
            "section": "Version fran\u00e7aise",
            "ref_spans": []
        },
        {
            "text": "Dans ce n\u00b0 des Annales d\u2019Endocrinologie, le lecteur trouvera les r\u00e9ponses aux questions que pose le vieillissement, qui fait l\u2019objet de toute l\u2019attention du corps m\u00e9dical, dans la prise en charge de la pathologie thyro\u00efdienne. Ce consensus coordonn\u00e9 par Philippe Caron est remarquable, pratique et exhaustif. Il repose sur une grande exp\u00e9rience clinique de ses auteurs.",
            "cite_spans": [],
            "section": "Version fran\u00e7aise",
            "ref_spans": []
        },
        {
            "text": "The authors declare that they have no competing interest.",
            "cite_spans": [],
            "section": "Disclosure of interest",
            "ref_spans": []
        }
    ],
    "ref_entries": {},
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "in name of the working group \u201cdrugs and COVID-19\u201d of the \u201cSoci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique\u201d Renin-angiotensin-aldosterone system and COVID-19 infections",
            "authors": [
                {
                    "first": "J.",
                    "middle": [],
                    "last": "Alexandre",
                    "suffix": ""
                },
                {
                    "first": "J.L.",
                    "middle": [],
                    "last": "Cracowski",
                    "suffix": ""
                },
                {
                    "first": "V.",
                    "middle": [],
                    "last": "Richard",
                    "suffix": ""
                },
                {
                    "first": "B.",
                    "middle": [],
                    "last": "Bouhanick",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Annals of Endocrinology",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "TLR7 escapes from X chromosome inactivation in immune cells",
            "authors": [
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Souyris",
                    "suffix": ""
                },
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Cenac",
                    "suffix": ""
                },
                {
                    "first": "P.",
                    "middle": [],
                    "last": "Azar",
                    "suffix": ""
                },
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Daviaud",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Canivet",
                    "suffix": ""
                },
                {
                    "first": "S.",
                    "middle": [],
                    "last": "Grunenwald",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Science Immunology",
            "volume": "3",
            "issn": "19.",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.1126/sciimmunol.aap8855"
                ]
            }
        },
        "BIBREF2": {
            "title": "Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study",
            "authors": [
                {
                    "first": "F.C.",
                    "middle": [],
                    "last": "Wu",
                    "suffix": ""
                },
                {
                    "first": "A.",
                    "middle": [],
                    "last": "Tajar",
                    "suffix": ""
                },
                {
                    "first": "S.R.",
                    "middle": [],
                    "last": "Pye",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "J Clin Endocrinol Metab",
            "volume": "93",
            "issn": "",
            "pages": "2737-2745",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "ACE2 expression in kidney and testis may cause kidney and testis damage After 2019 -nCoV Infection",
            "authors": [
                {
                    "first": "C.",
                    "middle": [],
                    "last": "Fan",
                    "suffix": ""
                },
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Kai",
                    "suffix": ""
                },
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Yanhong",
                    "suffix": ""
                },
                {
                    "first": "L.",
                    "middle": [],
                    "last": "Wei",
                    "suffix": ""
                },
                {
                    "first": "W.",
                    "middle": [],
                    "last": "Jianqing",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Kidney International",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF4": {
            "title": "COVID-19: consider cytokine storm syndromes and immunosuppression",
            "authors": [
                {
                    "first": "P.",
                    "middle": [],
                    "last": "Mehta",
                    "suffix": ""
                },
                {
                    "first": "D.F.",
                    "middle": [],
                    "last": "McAuley",
                    "suffix": ""
                },
                {
                    "first": "M.",
                    "middle": [],
                    "last": "Brown",
                    "suffix": ""
                },
                {
                    "first": "E.",
                    "middle": [],
                    "last": "Sanchez",
                    "suffix": ""
                },
                {
                    "first": "R.S.",
                    "middle": [],
                    "last": "Tattersall",
                    "suffix": ""
                },
                {
                    "first": "J.J.",
                    "middle": [],
                    "last": "Manson",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "10229",
            "pages": "1033-1034",
            "other_ids": {
                "DOI": [
                    "10.1016/S0140-6736(20)30628-0"
                ]
            }
        },
        "BIBREF5": {
            "title": "The role of ACTH and corticosteroids for sepsis and septic shock: an update",
            "authors": [
                {
                    "first": "D.",
                    "middle": [],
                    "last": "Annane",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Front Endocrinol (Lausanne)",
            "volume": "7",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": [
                    "10.3389/fendo.2016.00070"
                ]
            }
        },
        "BIBREF6": {
            "title": "Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury",
            "authors": [
                {
                    "first": "C.D.",
                    "middle": [],
                    "last": "Russell",
                    "suffix": ""
                },
                {
                    "first": "J.E.",
                    "middle": [],
                    "last": "Millar",
                    "suffix": ""
                },
                {
                    "first": "J.K.",
                    "middle": [],
                    "last": "Baillie",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Lancet",
            "volume": "395",
            "issn": "",
            "pages": "473-475",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "The transition from reimagining to recreating health care is now",
            "authors": [
                {
                    "first": "J.E.",
                    "middle": [],
                    "last": "Hollander",
                    "suffix": ""
                },
                {
                    "first": "F.D.",
                    "middle": [],
                    "last": "Sites",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "NEJM Catalyst",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        }
    }
}